{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:45:10Z","timestamp":1787165110141,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Endocrine disorders in patients with neurofibromatosis type 1 (NF1) are well established, but have been mainly described in single case reports or small series. Our aim is to characterize the endocrine manifestations of a NF1 paediatric population in a single centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective analysis of paediatric NF1 patients followed in the Endocrinology Department of Portuguese Institute of Oncology of Lisbon between 1997 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were identified using our centre's NF1 database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 181 patients (100 males) were included in the study. The overall prevalence of endocrinopathies was 23.2%, with a significantly higher rate in patients with optic pathway glioma (OPG) compared with those without (32.9% vs. 16.7%, P = .011). Puberty disorders were the most common endocrine dysfunction (12.2%), more frequent in children with OPG (19.2% vs. 7.4%, P = .011). Growth hormone deficiency (GHD) was the second most prevalent (9.9%), also more common among children with OPG (17.8% vs. 4.9%, P = .004). Less frequent abnormalities included central hypogonadism (n = 2, 1.1%), observed only in patients without OPG, and central hypothyroidism with ACTH deficiency (0.6%) in a child with panhypopituitarism. Primary hypothyroidism with thyroid nodules was identified in 1 patient (0.6%), and gynaecomastia was noted in 4 children (2.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Puberty disorders and GHD were the most frequent disorders in our cohort. This study highlights the high prevalence of different endocrine manifestations associated with NF1, even without OPG, reinforcing the need to develop referral criteria and follow-up protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf147","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:51:59Z","timestamp":1753271519000},"page":"216-222","source":"Crossref","is-referenced-by-count":1,"title":["Endocrine manifestations in a paediatric cohort of 181 patients with neurofibromatosis type 1"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-4982","authenticated-orcid":false,"given":"Catarina","family":"Regala","sequence":"first","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-9791","authenticated-orcid":false,"given":"Daniela","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Maciel","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Dam\u00e1sio","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-3617","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Passos","sequence":"additional","affiliation":[{"name":"Neurology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Donato","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisboa 1099-023 ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"3","key":"2025081213293482800_lvaf147-B1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and mortality of neurofibromatosis: a total population study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2025081213293482800_lvaf147-B2","volume-title":"Neurofibromatosis","author":"Le","year":"2024"},{"issue":"1","key":"2025081213293482800_lvaf147-B3","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"2025081213293482800_lvaf147-B4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.3390\/cancers11111790","article-title":"Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations","volume":"11","author":"Cassina","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025081213293482800_lvaf147-B5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/cancers12010114","article-title":"An update on neurofibromatosis type 1-associated gliomas","volume":"12","author":"Lobbous","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"(01|1)","key":"2025081213293482800_lvaf147-B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1055\/s-0041-1742197","article-title":"Prevalence of associated endocrine diseases in patients with neurofibromatosis type 1","volume":"12","author":"Alshahrani","year":"2022","journal-title":"Avicenna J Med"},{"issue":"4","key":"2025081213293482800_lvaf147-B7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.25753\/BirthGrowthMJ.v31.i4.25986","article-title":"Endocrine disorders in children with neurofibromatosis type 1: what to look for?","volume":"31","author":"Rangel","year":"2022","journal-title":"REVNEC"},{"issue":"3","key":"2025081213293482800_lvaf147-B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000458525","article-title":"Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma","volume":"87","author":"Sani","year":"2017","journal-title":"Horm Res Paediatr"},{"issue":"16","key":"2025081213293482800_lvaf147-B9","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","article-title":"Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy","volume":"24","author":"Sharif","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025081213293482800_lvaf147-B10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/ICU.0000000000000587","article-title":"Current treatment of optic nerve gliomas","volume":"30","author":"Farazdaghi","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"2025081213293482800_lvaf147-B11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000369802","article-title":"Endocrine implications of neurofibromatosis 1 in childhood","volume":"83","author":"Bizzarri","year":"2015","journal-title":"HormRes Paediatr"},{"issue":"4","key":"2025081213293482800_lvaf147-B12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1542\/peds.100.4.667","article-title":"Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1","volume":"100","author":"Cnossen","year":"1997","journal-title":"Pediatrics"},{"issue":"5","key":"2025081213293482800_lvaf147-B13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0022-3476(97)70117-3","article-title":"Precocious puberty in children with neurofibromatosis type 1","volume":"131","author":"Habiby","year":"1997","journal-title":"J Pediatr"},{"issue":"1","key":"2025081213293482800_lvaf147-B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/BF03401416","article-title":"Central precocious puberty due to hypothalamic hamartoma in neurofibromatosis type 1","volume":"15","author":"Bartolini","year":"2016","journal-title":"Hormones (Athens)"},{"issue":"1","key":"2025081213293482800_lvaf147-B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s42000-022-00411-9","article-title":"Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients","volume":"22","author":"Pinheiro","year":"2023","journal-title":"Hormones (Athens)"},{"issue":"1","key":"2025081213293482800_lvaf147-B16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0022-3476(97)70327-5","article-title":"Precocious puberty in two children with neurofibromatosis type I in the absence of optic chiasmal glioma","volume":"130","author":"Zacharin","year":"1997","journal-title":"J Pediatr"},{"issue":"3","key":"2025081213293482800_lvaf147-B17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archpedi.1970.02100080149020","article-title":"Endocrine manifestations of neurofibromatosis in children","volume":"120","author":"Saxena","year":"1970","journal-title":"Am J Dis Child"},{"issue":"5","key":"2025081213293482800_lvaf147-B18","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1210\/jcem.87.5.8481","article-title":"Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height","volume":"87","author":"Lazar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025081213293482800_lvaf147-B19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/(SICI)1096-8628(19991203)87:4&lt;317::AID-AJMG7&gt;3.0.CO;2-X","article-title":"Neurofibromatosis type 1 growth charts","volume":"87","author":"Clementi","year":"1999","journal-title":"Am J Med Genet"},{"issue":"5","key":"2025081213293482800_lvaf147-B20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0887-8994(00)00123-5","article-title":"Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions","volume":"22","author":"Vassilopoulou-Sellin","year":"2000","journal-title":"Pediatr Neurol"},{"issue":"19","key":"2025081213293482800_lvaf147-B21","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/hmg\/ddn194","article-title":"Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis","volume":"17","author":"Hegedus","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2025081213293482800_lvaf147-B22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"issue":"6","key":"2025081213293482800_lvaf147-B23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1542\/peds.103.6.1257","article-title":"Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study","volume":"103","author":"Carmi","year":"1999","journal-title":"Pediatrics"},{"issue":"Supplement","key":"2025081213293482800_lvaf147-B24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1515\/JPEM.2000.13.S1.841","article-title":"Neurofibromatosis type 1 and precocious puberty","volume":"13","author":"Virdis","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"2025081213293482800_lvaf147-B25","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1002\/ajmg.a.38308","article-title":"Growth hormone excess in children with neurofibromatosis type-1 and optic glioma","volume":"173","author":"Cambiaso","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"8","key":"2025081213293482800_lvaf147-B26","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/jcm11082168","article-title":"Neurofibromatosis type 1 has a wide spectrum of growth hormone excess","volume":"11","author":"Hannah-Shmouni","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"2025081213293482800_lvaf147-B27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00238-010-0469-6","article-title":"Prepubertal unilateral gynecomastia: a report of two cases","volume":"34","author":"Hoevenaren","year":"2011","journal-title":"Eur J Plast Surg"},{"issue":"9","key":"2025081213293482800_lvaf147-B28","first-page":"590","article-title":"Disorders of puberty: an approach to diagnosis and management","volume":"96","author":"Klein","year":"2017","journal-title":"Am Fam Physician"},{"issue":"1","key":"2025081213293482800_lvaf147-B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1365-2265.1997.2211032.x","article-title":"Endocrine outcome in long-term survivors of low-grade hypothalamic\/chiasmatic glioma","volume":"47","author":"Collet-Solberg","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025081213293482800_lvaf147-B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MED.0b013e32834ec952","article-title":"Diagnosis of growth hormone deficiency in childhood","volume":"19","author":"Stanley","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2025081213293482800_lvaf147-B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.coemr.2019.04.007","article-title":"Opioid-induced androgen deficiency (OPIAD): prevalence, consequence, and efficacy of testosterone replacement","volume":"6","author":"Ho","year":"2019","journal-title":"Curr Opin Endocr Metab Res."},{"issue":"11","key":"2025081213293482800_lvaf147-B32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s12098-020-03284-1","article-title":"Neurofibromatosis type-1 and hypothyroidism","volume":"87","author":"Panda","year":"2020","journal-title":"Indian J Pediatr"},{"key":"2025081213293482800_lvaf147-B33","doi-asserted-by":"publisher","first-page":"910656","DOI":"10.1155\/2013\/910656","article-title":"Neurofibromatosis type 1 associated with Hashimoto's thyroiditis: coincidence or possible link","volume":"2013","author":"Nabi","year":"2013","journal-title":"Case Rep Neurol Med"},{"issue":"6","key":"2025081213293482800_lvaf147-B34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4274\/balkanmedj.2015.1717","article-title":"Endocrinological evaluations of a neurofibromatosis type 1 cohort: is it necessary to evaluate autoimmune thyroiditis in neurofibromatosis type 1?","volume":"34","author":"G\u00fcler","year":"2017","journal-title":"Balkan Med J"},{"issue":"5","key":"2025081213293482800_lvaf147-B35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s004280100399","article-title":"Gynecomastia in type-1 neurofibromatosis with features of pseudoangiomatous stromal hyperplasia with giant cells. Report of two cases","volume":"438","author":"Damiani","year":"2001","journal-title":"Virchows Arch"},{"issue":"4","key":"2025081213293482800_lvaf147-B36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00428-014-1715-2","article-title":"Pseudoangiomatous stromal hyperplasia with multinucleated stromal giant cells is neither exceptional in gynecomastia nor characteristic of neurofibromatosis type 1","volume":"466","author":"Pi\u017eem","year":"2015","journal-title":"Virchows Arch"},{"issue":"8","key":"2025081213293482800_lvaf147-B37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0046-8177(81)80180-3","article-title":"Pseudogynecomastia due to neurofibromatosis\u2013a light microscopic and ultrastructural study","volume":"12","author":"Lipper","year":"1981","journal-title":"Hum Pathol"},{"key":"2025081213293482800_lvaf147-B38","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/BCTT.S111397","article-title":"Increased risk of breast cancer in neurofibromatosis type 1: current insights","volume":"9","author":"Howell","year":"2017","journal-title":"Breast Cancer (Dove Med Press)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf147\/63843864\/lvaf147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/2\/216\/63843864\/lvaf147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/2\/216\/63843864\/lvaf147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:29:37Z","timestamp":1755019777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/2\/216\/8212125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf147","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,25]]}}}